Skip to main content
. 2012 Aug 20;17(9):1213–1220. doi: 10.1634/theoncologist.2011-0467

Table 3.

Toxicity for the uterine group, nonuterine group, and all sarcomas

graphic file with name onc00912-1068-t03.jpg

Data are presented as the percentage of cycles for which patients experienced toxicity. Total number of cycles for each regimen is as follows: 103 gemcitabine-only and 111 gemcitabine + docetaxel for the uterine group; 104 gemcitabine-only and 95 gemcitabine + docetaxel for the nonuterine group; and 207 gemcitabine-only and 206 gemcitabine + docetaxel for all sarcomas.

Abbreviations: D, docetaxel; G, gemcitabine.